Opioid-Induced Constipation (OIC) Drug Market Comprehensive Insight by Growth Rate, Industry Status, Forecast till 2029
Opioid-Induced Constipation (OIC) Drug Market is anticipated to grow at a significant CAGR during the forecast period. The major factor that is expected to boost the market growth includes rising number of geriatric patients as these patients use opioid analgesics such as morphine, hydromorphone, codeine, etc. as a prescription for chronic non-cancer pain which has severe adverse effects on the digestive system resulting in huge demand for OIC drugs. For instance, according to National Center for Biotechnology Information report published in November 2019, the prevalence of distention, bloating and other GI symptoms of OIC associated with the opioid analgesic medication among non-cancer patients ranges from over 40% to 60% globally every year.
Thus, the rising volume of
patient pool with opioid users demands efficient medication for the OIC
ailments which is likely to boost the market during the forecast period.
Furthermore, the availability of Relistor in both tablets and subcutaneous
injection form, which was found to be more effective at reversing OIC compared
to other drugs are likely to drive the relistor segment and contribute to the
global market revenue during the forecast period.
Key Strategic Initiatives
• In
February 2021, RedHill Biopharma Ltd. announced agreements with Cosmo
Pharmaceuticals NV to manufacture two key products; RedHill's largest selling
product in the US, Movantik(?-opioid receptor antagonist), and RHB-204,
currently in a Phase 3 US study as a stand-alone, first-line
orally-administered treatment for pulmonary nontuberculous mycobacteria (NTM)
disease.
• In
April 2020, AstraZeneca has completed an agreement to sublicense its global
rights excluding Europe, Canada and Israel to RedHill Biopharma (RedHill) for
Movantik (naloxegol), which is used in the treatment of opioid-induced
constipation in adult patients with chronic non-cancer pain.
• In
April 2019, Sandoz announced that it has signed an agreement with Shionogi
& Co Ltd for commercialization of Rizmoic (naldemedine), a once-daily
200-microgram oral tablet to treat opioid-induced constipation (OIC) in adult
patients in the key European markets of Germany, the UK, and the Netherlands,
plus right of first refusal for certain other European markets.
To Request a Sample of our Report on Opioid-Induced
Constipation (OIC) Drug Market: https://www.omrglobal.com/request-sample/opioid-Induced-constipation-oic-drug-market
Market Coverage
•
The market number available for – 2022-2030
•
Base year- 2022
•
Forecast period- 2023-2030
Segment
Covered-
·
By Product Type
·
By Prescription Type
Regions covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
Competitive Landscape:
Novartis International AG, Merck & Co., Inc., and AstraZeneca plc, among
others.
Opioid-Induced
Constipation (OIC) Drug Market Report by Segment
By Product Type
• Lubiprostone
• Relistor
• Methyl Naltrexone Bromide
• Naldemedine
• Alvimopan
• Others
By Prescription
Type
• Prescribed Drug
• Over-the-Counter Drug
A full Report of Opioid-Induced Constipation (OIC) Drug
Market is Available @
https://www.omrglobal.com/industry-reports/opioid-Induced-constipation-oic-drug-market
Opioid-Induced Constipation (OIC)
Drug Market Report by Region
North America
· United
States
· Canada
Europe
· UK
· Germany
· Spain
· France
· Italy
· Rest
of Europe
Asia-Pacific
· India
· China
· Japan
· South
Korea
· Rest
of APAC
Rest of the World
•
Latin America
•
Middle East and Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
For More Customized Data,
Request for Report Customization @ https://www.omrglobal.com/report-customization/opioid-Induced-constipation-oic-drug-market
About Orion Market Research
Orion Market
Research (OMR) is a market research and consulting company known for its crisp
and concise reports. The company is equipped with an experienced team of
analysts and consultants. OMR offers quality syndicated research reports,
customized research reports, consulting and other research-based services. The
company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services
through another subsidiary Encanto Technologies.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment